Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS) (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
This NA trial investigates Dyslipidemias and Hypertension and is currently completed. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 12 recorded versions since 2006 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2022 — Jul 2024 [monthly]
Completed NA
-
Dec 2021 — Jan 2022 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Completed NA
-
Jan 2021 — Sep 2021 [monthly]
Completed NA
-
Apr 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
May 2019 — Apr 2020 [monthly]
Active Not Recruiting NA
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting NA
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- Singulex
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .